Arbutus Biopharma Corp (NASDAQ: ABUS) on Tuesday, plunged -2.54% from the previous trading day, before settling in for the closing price of $3.55. Within the past 52 weeks, ABUS’s price has moved between $2.18 and $4.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 55.33%. The company achieved an average annual earnings per share of 11.82%. With a float of $147.38 million, this company’s outstanding shares have now reached $189.44 million.
The extent of productivity of a business whose workforce counts for 73 workers is very important to gauge. In terms of profitability, gross margin is 84.13%, operating margin of -1223.89%, and the pretax margin is -1137.64%.
Arbutus Biopharma Corp (ABUS) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arbutus Biopharma Corp is 22.22%, while institutional ownership is 53.49%. The most recent insider transaction that took place on Aug 14 ’24, was worth 32,637. In this transaction Director of this company sold 8,846 shares at a rate of $3.69, taking the stock ownership to the 46,069 shares. Before that another transaction happened on Feb 02 ’24, when Company’s Chief Medical Officer sold 4,358 for $2.31, making the entire transaction worth $10,078. This insider now owns 125,542 shares in total.
Arbutus Biopharma Corp (ABUS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 11.82% per share during the next fiscal year.
Arbutus Biopharma Corp (NASDAQ: ABUS) Trading Performance Indicators
Arbutus Biopharma Corp (ABUS) is currently performing well based on its current performance indicators. A quick ratio of 7.02 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 97.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.43, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.34 in one year’s time.
Technical Analysis of Arbutus Biopharma Corp (ABUS)
The latest stats from [Arbutus Biopharma Corp, ABUS] show that its last 5-days average volume of 0.72 million was inferior to 1.08 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 26.72%. Additionally, its Average True Range was 0.15.
During the past 100 days, Arbutus Biopharma Corp’s (ABUS) raw stochastic average was set at 11.23%, which indicates a significant decrease from 23.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.66% in the past 14 days, which was higher than the 39.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.75, while its 200-day Moving Average is $3.44. Now, the first resistance to watch is $3.56. This is followed by the second major resistance level at $3.65. The third major resistance level sits at $3.72. If the price goes on to break the first support level at $3.40, it is likely to go to the next support level at $3.33. The third support level lies at $3.24 if the price breaches the second support level.
Arbutus Biopharma Corp (NASDAQ: ABUS) Key Stats
Market capitalization of the company is 655.65 million based on 189,492K outstanding shares. Right now, sales total 18,140 K and income totals -72,850 K. The company made 1,340 K in profit during its latest quarter, and -19,720 K in sales during its previous quarter.
